Bob Kramer, Emergent

The man­u­fac­tur­ing hold at Emer­gen­t's Bal­ti­more Bayview plant could be com­ing to an end — re­port

Mary­land’s Emer­gent BioSo­lu­tions has been forced to sit on its own hands for more than a month af­ter shut­ting down pro­duc­tion at a Bal­ti­more plant blast­ed for screw­ing up mil­lions of dos­es of two Covid-19 vac­cines. Now, with a laun­dry list of qual­i­ty is­sues ap­par­ent­ly solved, Emer­gent is re­port­ed­ly days away from get­ting its lines rolling once again.

J&J is ex­pect­ed to an­nounce that con­t­a­m­i­na­tion prob­lems at Emer­gent’s Bal­ti­more Bayview plant have been re­solved and pro­duc­tion is set to re­sume, The Wall Street Jour­nal re­port­ed Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.